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Abstract Purpose: AQ4N is a novel bioreductive prodrug under clinical investigation. Preclinical evidence
shows that AQ4N penetrates deeply within tumors and undergoes selective activation to form
AQ4, apotent topoisomerase II inhibitor, inhypoxic regionsof solid tumors.Thisproof-of-principle,
phase I study evaluated the activation, hypoxic selectivity, and safety of AQ4N in patients with
advanced solid tumors.
Experimental Design:Thirty-two patients with cancer (8 glioblastoma, 9 bladder, 8 head and
neck, 6 breast, and1cervix) received a single 200 mg/m2 dose of AQ4N before elective surgery.
AQ4 and AQ4N levels in 95 tissues (tumor, healthy tissue) were assessed by liquid chromato-
graphy-tandem mass spectrometry. Tissue sections were also analyzed for AQ4 fluorescence
using confocal microscopy, and for expression of the hypoxia-regulated glucose transporter,
Glut-1.
Results:ActivatedAQ4was detected in all tumor sampleswithhighest levels present in glioblas-
toma (mean1.2 Ag/g) and head and neck (mean 0.65 Ag/g) tumors; 22 of 32 patients had tumor
AQ4concentrationsz0.2 Ag/g, levels previously shown tobe active inpreclinical studies. In 24 of
30 tumor samples, AQ4 was detected at higher concentrations than in adjacent normal tissue
(tumor to normal ratio range1.1-63.6); distant skin samples contained very low concentrations of
AQ4 (mean 0.037 Ag/g).Microscopic evaluationof tumor sections revealed that AQ4 colocalized
within regions ofGlut-1+hypoxic cells.
Conclusions: AQ4N was activated selectively in hypoxic regions in human solid tumors.
Intratumoral concentrations of AQ4 exceeded those required for activity in animal models and
support the evaluation of AQ4N as a novel tumor-targeting agent in future clinical studies.
It is well recognized that the abnormal vasculature of most
solid tumors results in the poor delivery of oxygen and
nutrients to localized regions within tumors (1–4). These
regions of low oxygen concentration (hypoxia) are character-
istic of many solid tumors, in contrast to healthy tissue, which
is well vascularized. Hypoxia triggers changes in the transcrip-
tional regulation of a plethora of genes involved in cellular
metabolism, angiogenesis, and metastasis, further propagating
tumor growth and spread (1, 5–7).
Hypoxic tumor cells are resistant to radiotherapy as well as
cytotoxic agents (4, 8–11). Several mechanisms contribute to
this, including direct requirement of oxygen for ionizing
radiation damage, reduced penetration and delivery of chemo-
therapeutic agents, and the protective effects of hypoxia-
regulated genes. These factors, coupled with the increased
genetic instability observed in hypoxic cells, facilitate the
selection of resistant clones, tumor repopulation, and treatment
failure (12–14). Indeed, the expression of hypoxia-regulated
markers such as the glucose transporter-1 (Glut-1) has been
associated with poor prognosis and/or treatment failure in a
range of solid tumors (15–19). There is, therefore, a strong
rationale for the development of novel agents that specifically
target treatment-resistant and hypoxic regions of tumors with
minimal toxicity to normal tissues.
One such agent under clinical investigation is AQ4N
(banoxantrone; 1,4-bis {[2-(dimethylamino)ethyl]amino}-
5,8-dihydroxyanthracene-9, 10-dione bis-N-oxide), a novel
prodrug that was designed to be activated to a potent cytotoxin
in hypoxic tumor regions (20–23). It is postulated that the
combination of AQ4N with conventional therapeutic agents
may facilitate the targeting of both normoxic and hypoxic
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regions of the tumor microenvironment. Indeed, AQ4N has
been shown to enhance the therapeutic response to radiation
(24, 25), cisplatin (25, 26), and other chemotherapies (25, 27,
28) in preclinical models.
AQ4N is relatively nontoxic until it is bioreduced in hypoxic
cells by a two-step enzymatic reduction to form AQ4M, a short-
lived mono-N-oxide intermediate, and then to the ditertiary
cationic amine, AQ4, which is a potent cytotoxin. AQ4, but not
AQ4N, intercalates DNA with high affinity and functions as a
potent inhibitor of topoisomerase II (29). Bioreduction of
AQ4N occurs strictly in the absence of oxygen and seems to be
catalyzed by a number of cytochrome P450 (CYP) enzymes
(30–32), which are commonly up-regulated in tumors
(33–35). The high-affinity DNA binding limits diffusion of
AQ4 outside of the tumor microenvironment, resulting in
minimal systemic toxicity. Moreover, early clinical trials have
shown that AQ4N is well-tolerated in patients without evidence
of any major systemic toxicities at doses up to 447 mg/m2 when
given in combination with radiation (36) or 768 mg/m2 given
weekly as a single agent (37). In this study, patients received a
single 200 mg/m2 dose of AQ4N as this represented a margin of
substantial safety before surgery.
This translational, proof-of-principle study was designed to
establish whether AQ4N was preferentially activated in tumors
rather than normal tissue, and whether the activated AQ4
metabolite selectively accumulated in hypoxic regions. A
spectrum of solid tumor and normal tissues were biopsied
following scheduled surgical resection and examined for levels
of the AQ4N prodrug and its activated form, AQ4, using mass
spectrometry. In addition, the tissue distribution of AQ4 in
relation to tumor hypoxia was assessed using confocal
microscopy and by immunohistochemical detection of the
Glut-1 hypoxia marker.
Materials andMethods
Patient selection. Patients with histologic or cytologic confirmation
of malignancy, who were candidates for elective surgery for tumor
removal or reduction, were eligible; for glioblastoma multiforme
(GBM) patients, a firm radiological diagnosis was accepted. Patients
were required to be z18 years of age; with adequate bone marrow, liver,
and kidney reserve; and to have provided written informed consent.
Patients were ineligible if they had received radiotherapy (except
limited field palliative treatment), endocrine therapy, immunotherapy,
or chemotherapy treatment; or if they had received major thoracic/
abdominal surgery within 4 weeks of study entry; patients were also
required to have recovered from reversible toxicities of any prior
therapy. Patients with evidence of peripheral or central cyanosis, any
history of serious or uncontrolled ischemic heart disease, peripheral
cerebrovascular disease, or nonspecific chest pain were all ineligible.
Pregnant or lactating women were not eligible.
Study design, dosage, and drug administration. Patient history,
physical examination, electrocardiogram, and routine clinical labora-
tory studies were conducted within 14 days of drug administration.
Each patient received a single 200 mg/m2 dose of AQ4N by i.v. infusion
over f30 min. No other cytotoxic medication was administered.
AQ4N was provided in vials containing 150 mg AQ4N as the free
base. Each vial was reconstituted with sterile water to achieve a
concentration of 25 mg/mL. The reconstituted solution was mixed
aseptically with 250 mL 0.9% NaCl solution and infused through an in-
line filter.
Tumor biopsy sampling and procedure. Approximately 12 to 36 h
following AQ4N administration, multiple samples of tumor and
normal tissue (if available) were surgically resected from each patient.
Tissue specimens were washed thrice in ice-cold 0.9% NaCl solution,
blotted, and frozen in liquid N2 and stored at -80jC pending analysis.
The mean time of delay from resection of tissues to freezing was
f2 min. Samples were divided and analyzed for drug levels by mass
spectral analysis and for hypoxia using immunohistochemical staining
as described below.
Pharmacokinetic sampling and assays. Blood samples were collected
immediately before the end of AQ4N infusion and just before the
surgical resection. AQ4N, AQ4M, and AQ4 were extracted from plasma
using MCX solid phase extraction well plates (Waters Corporation) and
separated by reverse-phase high-performance liquid chromatography
using an Astec polymer C18 column as previously described (38, 39).
Each compound was detected using a tandem quadruple mass
spectrometer. The linear range for the assay was 10 to 2,000 ng/mL
for AQ4N and AQ4M and 2 to 400 ng/mL for AQ4. The assay precision
ranged from 6.0% to 8.2% for AQ4N, 3.7% to 4.4% for AQ4M, and
3.6% to 5.3% for AQ4, and was determined to have >92% accuracy. The
lower limit of quantification was 2 ng/mL for AQ4 and 10 ng/mL for
AQ4N.
Analysis of AQ4 and AQ4N in tissue samples. AQ4N and AQ4 were
extracted from tissue samples by homogenizing samples in ice-cold
methanol containing 0.2% hydrogen peroxide and centrifuged to
precipitate proteins. Supernatants were subjected to high-performance
liquid chromatography analysis with detection by diode array and triple
quadrupole mass spectrometry (36).
The linear range for the assay based on drug-free H460 xenograft
homogenates supplemented with AQ4N or AQ4 was 1 to 1,000 ng/mL
for AQ4N and AQ4M and 2 to 400 ng/mL for AQ4. All standards and
samples were kept on ice in the dark as a precautionary measure. Stock
standards of AQ4N and AQ4 were prepared in 10 mg/mL DMSO and
diluted in water. QC samples of AQ4 and AQ4N were prepared from
human H460 tumor homogenates at a concentration of 0.5 Ag/mL.
Accuracy and precision values of <30% were considered acceptable.
Immunohistochemistry. Formalin-fixed, paraffin-embedded tumor
sections were dewaxed in xylene and rehydrated using a series of
ethanol solutions of increasing dilution. One tissue section was stained
with hematoxylin to confirm the presence and quality of tumor. Before
staining tissues for Glut-1, 4-Am-thick sections were dewaxed in xylene,
passed through graded alcohols to water, exposed to 1% hydrogen
peroxide for 30 min at room temperature, and then heated in citrate
buffer for 24 min. Sections were incubated for 30 min with 15:1,000
diluted normal goat blocking serum (Vector Laboratories) to minimize
nonspecific binding and then incubated with rabbit anti-human Glut-1
antibody (DakoCytomation) at a 1:25 dilution for 90 min at room
temperature. Biotinylated anti-rabbit immunoglobulin (Vector Labora-
tories) as a secondary antibody was applied at 1:200 dilution for
30 min at room temperature followed by incubation with an avidin
biotinylated enzyme complex solution (Vectastain, Vector Laboratories)
for an additional 30 min at room temperature. Glut-1 antibody on the
tissue sections was visualized using 3¶,3-diaminobenzidine, and
sections were counterstained with hematoxylin solution, dehydrated,
and coverslipped. As a negative control, tissues were also stained with a
nonimmunized rabbit serum at the same concentrations as the primary
antibody.
Sections were viewed at a magnification of 100 and scored in a
blinded fashion by two independent observers according to the
proportion of Glut-1 staining (plasma membrane only) in the entire
section [0, no staining; 1, light staining (0-5%); 2, medium staining (5-
15%); 3, heavy staining (15-30%); and 4, intense staining (>30%)],
according to previously published criteria (16). Edge effects, and
necrotic and stromal areas were ignored.
Confocal microscopy. Cryosections of 10 to 20 Am thickness were
prepared under minimal light exposure and stored at -80jC.
Incubations and washes were restricted to minimize potential washout
of drug from sections. Sections were fixed in 4% paraformaldehyde for
5 min and washed with PBS. The sections were incubated for 5 min
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with anti–Glut-1 antibody (GT12-A, Alpha Diagnostics, Inc.), detected
with a Alexa Flour 488–conjugated anti-rabbit secondary or with a
mouse monoclonal anti–GFAP-Alexa Fluor 488 conjugate (Invitrogen).
Antibodies were diluted in PBS containing 0.25% (v/v) fish skin gelatin
(Sigma). Following three brief PBS washes, samples were mounted
using an aqueous mountant with 4¶,6-diamidino-2-phenylindole
(DAPI; Vector Laboratories) and imaged on a Zeiss LSM 510 meta-
confocal microscope using a 633-nm laser to excite AQ4 fluorescence as
described previously (40). 40 and 63 objectives were used with up
to 5 digital zoom as needed for each section. Differential interference
contrast imaging was used to detect cytoplasmic blebbing indicative of
apoptosis (41). Projected z-stacks were rendered using Volocity three-
dimensional imaging software (Improvision).
Statistical analysis. All statistical analysis was done using a two-
tailed Student’s t test using GraphPad Prism software (GraphPad
Software, Inc.). A P value of <0.05 was considered to be statistically
significant.
Results
Thirty-three patients from six centers in United Kingdom and
Latvia were enrolled between November 2004 and September
2005, of whom 32 received AQ4N and completed the study.
One patient enrolled in the study experienced a myocardial
infarction before surgery and was withdrawn from the study.
All subjects had solid tumors that required surgical resections of
the following indications: GBM (n = 8), head and neck
carcinoma (n = 8), bladder carcinoma (n = 9), breast carcinoma
(n = 6), and cervical carcinoma (n = 1). Most patients on the
study were treatment naive with the exception of two bladder
carcinoma patients who received either prior Bacillus Calmette-
Guerin or radiation treatment and one head and neck
carcinoma patient who received prior radiation therapy. Other
patient characteristics are shown in Supplementary Table S1.
Plasma and tissue levels of drug. Immediately before the end
of drug infusion, the mean (FSE) levels of AQ4N in the plasma
were 26.2 F 4.8 Ag/mL (Fig. 1). Plasma levels of the activated
metabolite, AQ4, following drug infusion represented <0.04%
of AQ4N levels measured (Supplementary Table S2). At the
time of surgery, AQ4N plasma levels were very low (89.8 F
25.0 ng/mL) and represented <0.4% of AQ4N levels measured
following infusion (Fig. 1) and there was no significant
correlation between the time interval between infusion and
surgery, and AQ4N levels before surgery (data not shown). This
confirms previous observations from clinical studies indicating
the rapid clearance of AQ4N from the systemic circulation
(36, 37). Importantly, the fully bioreduced AQ4 metabolite
could not be detected from the plasma at the time of surgery in
29 of 32 samples (Supplementary Table S2). Thus, little if any
AQ4N or AQ4 was present systemically when tumor and
normal tissue samples were taken, minimizing the possibility of
contamination from blood.
Ninety-five biopsy samples from 32 patients were analyzed
for AQ4N and AQ4 concentrations. Normal tissue samples
adjacent to the tumor were harvested in 30 of 32 patients as
well as distal skin (13 patients) and lymph nodes (8 patients).
The bioreduced AQ4 metabolite was detected in all tumor
samples, in most cases at higher concentrations than in the
corresponding normal tissues, demonstrating tumor activation
of the prodrug in man (Fig. 2; Supplementary Table S3). The
mean (FSE) tumor concentration of AQ4 from all patients was
0.93 F 0.37 Ag/g, compared with mean (FSE) normal tissue
concentrations of 0.15 F 0.05 Ag/g, demonstrating clear tumor
selectivity (P = 0.04). In contrast, AQ4N was only detected in 11
of 32 tumor samples and predominantly in bladder tissues. The
mean tissue concentrations of AQ4 and AQ4N for each tumor
type and the mean concentration ratios of tumor to normal are
shown in Table 1. The mean AQ4 tumor to normal ratio for the
majority of tumor types ranged from 3.1 to 19.2, clearly
demonstrating targeting of the cytotoxic metabolite to tumor
tissue (Table 1). The only exception was the single patient with
cervical cancer who had an AQ4 tumor to normal ratio of 0.5.
Variability of AQ4 levels within tumors was noted in this
study. For example, in one GBM patient, nine samples from
multiple sites within the tumor had AQ4 levels that ranged
from 0.034 to 0.65 Ag/g, with six of the nine samples having
concentrations that exceeded 0.2 Ag/g. Similarly, a bladder
tumor specimen from one patient contained AQ4 at a
concentration of 10.5 Ag/g, which was f30-fold higher than
the highest value of the other nine patients (Fig. 2). In three
bladder cancer patients, AQ4 levels in normal tissue exceeded
those in the corresponding tumor tissue. AQ4N was detected in
the majority of bladder tumor samples, in contrast with other
























































Fig. 1. Plasma levels of AQ4N immediately following
infusion and at time of surgery. Plasma concentrations
of AQ4N (ng/mL) from individual patients immediately after
dosing (solid diamonds) and immediately before surgical
resection (shaded squares).
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observed that lymph node specimens had relatively high levels
of AQ4 (Supplementary Table S3). For one GBM and two head
and neck patients, tumor samples from both peripheral and
internal regions of the tumor had higher AQ4 concentrations in
the central regions of the tumors.
Hypoxia detection by immunohistochemistry. To assess the
level of hypoxia in the biopsy samples, we elected to measure
the expression of Glut-1, an endogenous marker of tumor
hypoxia (15–19). A total of 70 biopsy samples from 30
patients were assessed by immunohistochemistry for Glut-1, to
assess the level of hypoxia within a section. Many tumor
sections displayed clear and extensive regions of Glut-1+
hypoxic cells in contrast to the majority of normal tissue
demonstrating little or no staining (Fig. 3; Supplementary
Table S4). The mean percentage of Glut-1+ cells for each tumor
type, except cervix, ranged from 11% to 46% (n = 28) in tumor
Table 1. Mean (FSE) levels of AQ4 and AQ4N (Ag/g) in tumor and normal samples
Tissue (n) AQ4 (Mg/g)* AQ4N (Mg/g)
Tumor Adjacent normal T:N ratioc Tumor Adjacent normal T:N ratioc
GBM (8) 1.17 F 0.54 0.09 F 0.05 19.2 0.10 F 0.09 0.04 F 0.01 2.46
Bladder (9) 1.34 F 1.15 0.25 F 0.11 8.5 8.41 F 8.05 0.14 F 0.07 61.2
Head and neck (8) 0.69 F 0.19 0.19 F 0.05 3.1 BLQ BLQ NA
Breast (6) 0.41 F 0.18 0.05 F 0.01 6.9 BLQ BLQ NA
Cervix (1) 0.02 0.04 0.5 BLQ BLQ NA
Skin (13) — 0.04 F 0.01 — 0.02 F 0.01 —
Lymph (8) — 0.19 F 0.06 — 0.01 F 0.01 —
Abbreviations: BLQ, below limit of quantification; T:N, tumor to normal ratio; NA, not applicable.
*Where more than one tumor sample was assayed for a patient, mean interpatient tumor values for those patients were used.
cMean of tumor to normal ratios for individual patients.
Fig. 2. Levels of bioreduced AQ4
metabolite in tumor and normal tissues.
AQ4 concentrations (Ag/g) from resected
tumors and corresponding adjacent normal
tissues from patients with GBM (n = 8),
bladder (n = 9), head and neck (n = 8),
breast (n = 6), and cervical (n = 1) cancers.
AQ4 was also measured in distal normal
skin samples (n = 13) and lymph nodes
(n = 8), when available.
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tissues in contrast to only 0% to 0.5% being observed in
normal tissues (n = 21; P < 0.05; Supplementary Table S4). In
general, tumor sections with considerable Glut-1 staining had
higher levels of AQ4, whereas sections with little or no staining
contained little AQ4 (Figs. 3 and 4). When samples were clas-
sified into three levels of AQ4 concentration, low (<0.2 Ag/g),
medium (0.2-1 Ag/g), and high (>1 Ag/g), AQ4 tumor
concentrations correlated with increased tumor hypoxia as
assessed by Glut-1+ staining (Fig. 4A). The mean (FSE) Glut-1
percentages for tissues classified as possessing high (>1 Ag/g)
AQ4 levels were significantly higher than those expressing low
(<0.2 Ag/g) AQ4 (46.4 F 10.3 versus 3.2 F 1.6, P < 0.001;
Fig. 4A), consistent with preferential activation of AQ4N within
the more hypoxic regions. Similarly, sections possessing >15%
Glut-1+ regions (scored 3 and 4) were observed to contain
significantly higher mean AQ4 levels than nonhypoxic tissues
with no Glut-1 expression (1.64F 0.76 versus 0.13F 0.04 Ag/g,
P < 0.005; Fig. 4B).
Correlation of Glut-1 and AQ4 by confocal microscopy. The
Glut-1 immunohistochemistry provided evidence for an asso-
ciation between levels of AQ4 in tumors and the degree of
hypoxia. We investigated this further by exploiting the intrinsic
fluorescence of AQ4 (40), which allows the drug to be visualized
in tumor sections using confocal microscopy. A total of seven
tumor samples from five patients with GBM (n = 2), bladder
(n = 1), head and neck (n = 1), and breast (n = 1) cancers were
analyzed by confocal microscopy and immunofluorescence.
AQ4-associated fluorescence was detected in two of four
GBM samples from two patients, and in each of the bladder
and head and neck tumor samples. In all samples examined,
AQ4 fluorescence was restricted within regions expressing the
highest levels of Glut-1+ (Fig. 5A-C). In one patient with
bladder cancer who had a high intratumoral concentration of
AQ4 (10.5 Ag/g), there was clear nuclear localization of AQ4,
which related closely to microregions of Glut-1+ cells (Fig. 5A).
In most other samples, AQ4-associated fluorescence accumu-
lated in heterogeneous speckles (Fig. 5B and C). AQ4 was also
detected in areas that lacked cellular architecture on differential
interference contrast imaging and nuclear DAPI staining,
features consistent with necrosis (Fig. 5 and data not shown).
In some cells peripheral to these necrotic regions, AQ4 was
found at high levels in cells exhibiting morphologic features of
apoptosis, including nuclear fragmentation and cytoplasmic
blebbing (Fig. 5D and data not shown).
Toxicity. In general, AQ4N was well tolerated. No deaths
occurred during the 30-day study period. Twenty-five patients
experienced a total of 99 adverse events, the majority of which
were mild to moderate in intensity. The most common adverse
events that occurred following treatment (z10%) included
nausea, postprocedural pain, headache, skin discoloration,
hypertension, hypotension, and pyrexia. The adverse events
that were considered likely to be drug related were generalized
gray/blue skin discoloration (seven adverse events) and fatigue
(two adverse events). No hematologic toxicities were noted.
Three patients experienced four serious adverse events. One
patient with a history of ischemic heart disease experienced a
myocardial infarction and left ventricular failure, which were
both considered to be possibly drug related by the treating
physician. The other two serious adverse events in two other
patients, worsening obstructive airways disorder and severe
postoperative infection, were not considered to be drug related.
All of these serious adverse events resolved.
Discussion
The key finding of this study has been to confirm the tumor
selectivity and hypoxia targeting of AQ4N in man. Our data
clearly show that the activated form of the prodrug, AQ4,
preferentially accumulates in tumor rather than in normal
tissues, is present at higher levels in tumors with greater degrees
of hypoxia, and seems to be localized within regions
comprising hypoxic tumor cells. This is the first time, to our
knowledge, that the activation of a bioreductive agent in
clinical tumor samples has been shown.
Fig. 3. Representative biopsy samples
for Glut-1hypoxia marker and AQ4 levels.
Representative sections from GBM, bladder,
head and neck, and breast tumor samples
and corresponding normal tissue sections
analyzed for Glut-1expression (brown
staining) following immunohistochemical
staining; approximate percentage of
Glut-1+ regions for each section is shown
beside each image. Concentrations of AQ4
(Ag/g) for each tumor sample are shown
beside the % Glut-1scores.
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AQ4N was designed to be an inactive prodrug in most
healthy tissues but would be selectively activated to a potent
cytotoxin in hypoxic regions that are characteristic of many
solid tumors. Previous clinical trials have indeed shown that
AQ4N is well tolerated in patients without evidence of any
major systemic toxicities at doses up to 768 mg/m2 given
weekly as a single agent (37) or 447 mg/m2 when given in
combination with radiotherapy (36). The traditional paradigm
for anticancer drug development would then be to undertake a
broad program of empirical phase II trials with tumor
shrinkage as the primary end point. This is, however, not
optimal for rationally designed agents. Moreover, the targeting
of hypoxic areas of tumors by AQ4N may not achieve sufficient
tumor debulking to satisfy conventional Response Evaluation
Criteria in Solid Tumors (43). Therefore, proof-of-principle
studies are vital if novel agents are to be developed rationally. A
previous phase I study of AQ4N and radiotherapy provided
preliminary data suggesting that AQ4 was generated preferen-
tially in esophageal cancers (36). There remained, however, a
need to show this effect definitively in patients with a spectrum
of tumors receiving AQ4N as a single agent, and to define the
relationship between tumor hypoxia and the accumulation of
the activated form of this prodrug.
The bioreduced, cytotoxic metabolite AQ4 was detected in all
tumor samples; the mean tumor to normal ratio for AQ4 in the
majority of tumor types ranged from 3.1 to 19.2, demonstrating
clear tumor selective activation. The only exception was a single
patient with cervical cancer who had a ratio of 0.5. By contrast,
tumor to normal ratios of AQ4 were particularly high in GBM
(mean 19.2). These data show that AQ4N effectively traverses
the blood-brain barrier and is selectively activated in GBM. The
absence of AQ4N bioactivation in normal tissues or in the
circulation is ideal for an anticancer prodrug and is consistent
with earlier reports demonstrating that AQ4N is well tolerated
in patients with solid tumor malignancies (36, 37).
Based on our immunohistochemical data, tumor biopsies
almost certainly included normoxic cells, suggesting that these
mean tumor concentrations of AQ4 most likely underestimate
the concentrations present in hypoxic areas of the tumors. In
addition, hypoxia is a dynamic process and is dependent on
both tumor vascularization and growth. The heterogeneity of
hypoxia would be expected to result in considerable variation
in the amounts of AQ4 generated in different regions of a
tumor. Interestingly, one patient had a 20-fold variance in AQ4
concentration in nine samples from the same tumor; in three
other cases where multiple samples of the same tumor were
analyzed, the central portion of the tumor had higher
concentrations of AQ4 than the peripheral area. This is
consistent with the expected regional differences in hypoxia,
although this hypothesis was not directly tested.
Whereas AQ4 was prevalent in tumor tissues, AQ4N was only
detected in 11 of 32 tumor samples and predominantly in
bladder tissues. At the time of surgery, AQ4N plasma levels
were very low, confirming previous observations of rapid
AQ4N clearance from the systemic circulation (36, 37); the
fully bioreduced AQ4 metabolite could be detected in plasma
at the time of surgery in only 3 of 32 samples. With little, if any,
AQ4N or AQ4 present in the plasma at surgery, the possibility
of contamination of tumor and normal tissue samples by blood
is minimized. Because AQ4N is eliminated through the
kidneys, AQ4N-rich urine bathes the bladder walls for some
hours following administration and may contribute to the
‘‘atypical’’ AQ4N accumulation in bladder cancer patients
observed in this study.
Having shown tumor selective activation of AQ4, we wanted
to establish that this was mediated by tumor hypoxia. Although
the clinical importance of hypoxia is widely recognized, there
remains controversy regarding how hypoxia is best quantified
(42). We elected to use an endogenous marker of hypoxia
rather than an exogenous bioreductive marker such as
pimonidazole to minimize the risk of any interaction between
test agents. Glut-1 is well recognized to be regulated by hypoxia
and there are numerous studies demonstrating its utility as a
marker of endogenous hypoxia as well as its association with
tumor aggressiveness and poor prognosis in a variety of
neoplasms (15–19, 44). The presence of Glut-1 is likely to
represent chronic hypoxia and may underrepresent transient
hypoxic episodes that frequently occur in tumors due to high
interstitial pressures and temporary vascular occlusion. We
would, however, expect AQ4N to be equally activated under
transient or chronic hypoxia, which may reduce the correlation
with Glut-1 staining. Therefore, the significant increase (P <
0.001) in Glut-1 staining in tumor samples compared with
normal tissue, and the clear association between increased
tissue AQ4 levels and high Glut-1 staining both support the
assertion that AQ4 is selectively activated in hypoxic tumors.
This conclusion was further supported by confocal microscopy,
where direct colocalization of AQ4 in hypoxic regions was
observed. These results are consistent with preclinical evidence
Fig. 4. Correlation of tumor hypoxia (Glut-1staining) and AQ4. A, percentage
of Glut-1+ regions for each section plotted against tissue samples that contained
low (0-0.2 Ag/g), medium (0.2-1 Ag/g), or high (>1 Ag/g) AQ4 concentrations.
Columns, mean; bars, SE. B, AQ4 tissue levels plotted against Glut-1score.
Columns, mean; bars, SE. Glut-1score: 0, no staining; 1, 0% to 5% Glut-1+; 2,
5% to15% Glut-1+, 3, 15% to 30% Glut-1+; 4, >30% Glut-1+.
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demonstrating tumor-hypoxia targeting of AQ4N in xenograft
models (28, 45–47).
The hypoxia-dependent activation of AQ4N also requires the
bioreductive activity of certain CYP enzymes (30, 31, 35).
Although some CYP isoforms, such as CYP 3A4, have been
shown to activate AQ4N more efficiently than others, multiple
CYP enzymes are capable of contributing to prodrug activation
(30, 31, 35, 48–50). Hence, we did not choose to assay the
biopsy samples for the expression of individual CYP enzymes. A
separate study has shown that microsome extracts from 20
clinical brain tumor specimens expressed different comple-
ments of CYP enzymes and could all activate AQ4N ex vivo
under anoxia, albeit with different efficiency (35). The
observation of high levels of AQ4 in multiple tumor samples
after a single administration of AQ4N does not suggest that
CYP expression is likely to be a limiting factor in the
effectiveness of AQ4N therapy.
In this study, single 200 mg/m2 doses of AQ4N were well
tolerated. This dose was selected based on a number of criteria.
Previous clinical studies have confirmed that doses of up to 447
Fig. 5. AQ4 colocalizes with Glut-1+ hypoxic tumor regions. Representative tumor sections analyzed by confocal microscopy. A to C, Glut-1+ staining (green), DAPI tumor
nuclei (blue), and AQ4-dependent fluorescence (red). D, glial fibrillary acidic protein tumor marker (green), AQ4 (red), and DAPI (blue). Scale bars (yellow), 10 Am.
A, bladder tumor (sample 0707). Bottom left, an overlay of AQ4 and DAPInuclear stain; bottom right, a merged image of Glut-1+, DAPI+, and AQ4+ sections. B, head and
neck tumor (sample 801). Bottom right, merged image of all three sections demonstrating colocalization of AQ4 drug within hypoxic Glut-1+ tumor regions. C, GBM tumor
(sample 0503). Bottom right, merged image of all three sections demonstrating colocalization of AQ4 drug within hypoxic Glut-1+ tumor regions.D, GBM tumor (sample
0503). Reconstructed three-dimensional z-stack image demonstrating AQ4 abundance in cells undergoing nuclear fragmentation, overlaying AQ4, DAPI, and GFAP.
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and 768 mg/m2 are safe and well tolerated (36, 37), so the
200 mg/m2 dose gave a considerable safety margin in the
presurgical setting, where AQ4N had not previously been
evaluated. Full pharmacokinetic profiles were not obtained in
the current study, but in an earlier study a single AQ4N dose of
176 mg/m2 had area-under-the-curve values of 46 to
86 Agh/mL (36). This compares with plasma area under the
curve of 50 Agh/mL in mice receiving 60 mg/kg of AQ4N, a
dose that has been shown to be efficacious in xenograft models
and that resulted in intratumoral AQ4 levels of 0.2 to 1.0 Ag/g
(47). In this present clinical study, intratumoral AQ4 levels
were observed to be >0.2 Ag/g in 30 of 32 patients (>90%),
further supporting the view that this dose may be potentially
therapeutic. Because we could not obtain serial tumor samples,
it was not possible to assess the kinetics of intratumoral AQ4
formation.
Taken together, these observations show that the low toxicity
prodrug AQ4N is converted to the active metabolite AQ4 in
hypoxic regions of tumors in man. Nevertheless, a number of
questions cannot be answered by the current study. First, we do
not know whether this will translate into enhanced therapeutic
benefit in patients with cancer. Second, it is unclear whether the
200 mg/m2 dose explored in this study is optimal. Third, it is
unknown whether patients with more hypoxic tumors will
achieve a better therapeutic outcome following AQ4N treat-
ment. This final question may be important in selecting
patients for future trials, but it is encouraging that selective
activation of AQ4N in significant areas of hypoxia were seen in
most tumors types studied. The current study provides a strong
rationale for trials addressing these and other questions.
In summary, we have shown proof-of-concept for the
preferential activation of AQ4N in hypoxic compartments of
several important solid tumors, leading to potentially thera-
peutic levels of a potent topoisomerase II poison in regions of
the tumor microenvironment that are typically refractory to
conventional chemotherapy and radiotherapy. In addition, this
study also confirmed that AQ4N effectively crosses the blood-
brain barrier, resulting in high levels of the activated AQ4
metabolite within primary brain tumors. These data encourage
the further clinical development of AQ4N for the treatment of
solid tumors including GBM.
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